Pre-administration of turmeric prevents methotrexate-induced liver toxicity and oxidative stress
BMC Complementary and Alternative Medicine, ISSN: 1472-6882, Vol: 15, Issue: 1, Page: 246
2015
- 89Citations
- 107Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations89
- Citation Indexes89
- 89
- CrossRef70
- Captures107
- Readers107
- 107
- Mentions1
- Blog Mentions1
- Blog1
Article Description
Background: Methotrexate (MTX) is an antimetabolite broadly used in treatment of cancer and autoimmune diseases. MTX-induced hepatotoxicity limits its application. We investigated hepatoprotective effects of turmeric in MTX-induced liver toxicity. Methods: All experiments were performed on male Wistar albino rats that were randomly divided into six groups. Group one received saline orally for 30 days (control group), groups two and three received turmeric extract (100, 200 mg/kg respectively) orally for 30 days, group four received single dose, of MTX IP at day 30, groups five and six received turmeric extract 100 and 200 mg/kg orally respectively for 30 days and single dose of methoterxate IP (20 mg/kg) at day 30. Four days after MTX injection animals were sacrificed and evaluated. Blood ALT and AST (indicators of hepatocyte injury), ALP and bilirubin (markers of biliary function), albumin (reflect liver synthetic function) as well as the plasma TAS concentration (antioxidant defenses) were determined. The cellular antioxidant defense activities were examined in liver tissue samples using SOD, CAT, and GSH-Px for the oxidative stress, and MDA for lipid peroxidation. In addition, liver damage was evaluated histopathologically. Results: MTX significantly induced liver damage (P < 0.05) and decreased its antioxidant capacity, while turmeric was hepatoprotective. Liver tissue microscopic evaluation showed that MTX treatment induced severe centrilobular and periportal degeneration, hyperemia of portal vein, increased artery inflammatory cells infiltration and necrosis, while all of histopathological changes were attenuated by turmeric (200 mg/kg). Conclusion: Turmeric extract can successfully attenuate MTX-hepatotoxicity. The effect is partly mediated through extract's antinflammatory activity.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84937710356&origin=inward; http://dx.doi.org/10.1186/s12906-015-0773-6; http://www.ncbi.nlm.nih.gov/pubmed/26199067; https://bmccomplementalternmed.biomedcentral.com/articles/10.1186/s12906-015-0773-6; https://dx.doi.org/10.1186/s12906-015-0773-6; https://bmccomplementmedtherapies.biomedcentral.com/articles/10.1186/s12906-015-0773-6; http://link.springer.com/article/10.1186/s12906-015-0773-6/fulltext.html; https://link.springer.com/track/pdf/10.1186/s12906-015-0773-6; https://link.springer.com/articles/10.1186/s12906-015-0773-6; https://link.springer.com/article/10.1186/s12906-015-0773-6; http://bmccomplementalternmed.biomedcentral.com/articles/10.1186/s12906-015-0773-6; https://bmccomplementmedtherapies.biomedcentral.com/counter/pdf/10.1186/s12906-015-0773-6; http://www.biomedcentral.com/1472-6882/15/246; https://bmccomplementalternmed.biomedcentral.com/track/pdf/10.1186/s12906-015-0773-6
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know